Date:March 12, 1948
Location:The Prime Minister's Private Study, South Block, New Delhi
The sun was setting over what would eventually be called Rashtrapati Bhavan, casting long amber shadows across Anirban Sen's desk. The day had been exhausting—hours of meetings with provincial administrators, budget negotiations, endless bureaucratic minutiae—but now, in the quiet of evening, he sat alone in his private study. The silence was broken only by the rhythmic ticking of a grandfather clock and the occasional rustle of papers as a breeze came through the half-open window.
In his hand was a telegram that had arrived just minutes earlier via secure diplomatic pouch from the United States. He had read it three times already, but he found himself reading it again, savoring the words:
> FROM: CONSULATE GENERAL, NEW YORK
> TO: PMO NEW DELHI
> CLASSIFICATION: CONFIDENTIAL
> SUBJECT: DR. SUBBAROW, YELLAPRAGADA
>
> SUBJECT HAS FORMALLY ACCEPTED THE APPOINTMENT AS DIRECTOR-GENERAL OF INDIAN COUNCIL OF MEDICAL RESEARCH. WILL DEPART LEDERLE LABORATORIES IMMEDIATELY. DR. SUBBAROW EXPRESSES PROFOUND GRATITUDE FOR THE OPPORTUNITY AND STATES HE IS 'COMING HOME TO PAY A DEBT THAT CANNOT BE CALCULATED IN DOLLARS OR MEASURED IN YEARS.' ARRIVAL EXPECTED MARCH 25 VIA PAN AMERICAN CLIPPER SERVICE. LEDERLE LABORATORIES SENIOR MANAGEMENT EXTREMELY DISTRESSED. HAVE OFFERED SUBSTANTIAL COUNTER-PROPOSAL INCLUDING EQUITY STAKE. SUBJECT DECLINED. REGARDS.
Anirban let out a long, slow breath, leaning back in his leather chair. He set the telegram down carefully on his desk, as though it were something precious and fragile. Yellapragada Subbarow. The name carried weight that few in India yet understood. The man who had co-discovered the role of ATP—adenosine triphosphate, the fundamental energy currency of all living cells. The biochemist who had developed folic acid synthesis and laid the groundwork for the first chemotherapy drugs. A giant of science working in the laboratories of Lederle in New York, making breakthrough after breakthrough that enriched American pharmaceutical companies while remaining virtually unknown to the country of his birth.
In the original timeline—the one Anirban remembered with the clarity of lived experience despite the impossibility of that memory—Yellapragada Subbarow would die this year, in 1948, at the age of fifty-three. A heart attack would take him suddenly, cutting short one of the most brilliant scientific careers of the century. He would die largely unrecognized, his contributions attributed to others, his genius overshadowed by the big names of Western science who built upon his work without proper acknowledgment.
But not in this timeline. Not if Anirban had anything to say about it.
His mind drifted back to a night in 1924—years ago now, though the memory remained vivid. A cold, rain-slicked night in a rural area outside of Chennai. Anirban had been younger then,approx 7-8 years old at that time, still learning to navigate the strange gift of foreknowledge that allowed him to see the paths of the original timeline branching away from the present he was actively reshaping. He had been on a tour of India with his guru, his teacher—a journey that was ostensibly for cultural and academic exchange of various parts of India, but for him a mission of strategic preservation, as Yellapragada was also a close person to his Guru, as his Guru is the senior of him when he is pursuing sainthood in Ramkrishna mission and has a good relationship.
They had traveled and staying with them for few days. And In that modest house struggling against the time, Just as Yellapragada Subbarow was receiving the first terrible news from India. His family back home was being ravaged by illness—tropical sprue, complications from malnutrition, the cascade of medical disasters that befell so many in British-ruled India where healthcare was a luxury few could afford. In the original timeline, Subbarow's young son had died. Others in the extended family had perished. The weight of that grief, combined with the guilt of being thousands of miles away pursuing his research while his family suffered, had anchored the scientist permanently to American soil. He had never returned to India, working until his death in the laboratories that valued his genius but never properly credited it.
Anirban and his guru had arrived at that doorstep of village at the exact moment of crisis, in the phase when it can be all controlled and they can be saved. Subbarow had been devastated, already making frantic arrangements to try to book passage home knowing he would likely arrive too late. But Anirban had carried with hiim something more valuable than money for passage: medical knowledge decades ahead of its time.
"There is something you can do from here," Anirban had told the distraught doctor who is treating them and family members of subbarow's and villagers . " these are the specific instructions use this. These medications, in these precise dosages. This treatment protocol for tropical sprue. These antibiotics— source them from the local pharmacy, and or this plants from aryuvedic clinics, here i have emergency medicine that can be used now"
Mr.Subbarow's family members had looked at the child with bewilderment. "How do you know this? Are you a doctor?"
"No, but there is no other option anyway" Anirban had replied, which was technically true if you counted the doctors who existed in the original timeline's future. "Trust me.Use these instructions immediately."
And miraculously, it had worked. . The son had survived. Others in the village had been treated using the protocols Anirban had provided. The family crisis had been averted.
Mr.Subbarow had never forgotten the young Indian child who had appeared at his moment of greatest need with medical knowledge that seemed impossibly advanced. Over the years, they had maintained occasional correspondence. Anirban had carefully cultivated the relationship, checking in periodically, making sure Subbarow knew that India had not forgotten him even if his adopted country failed to properly recognize his contributions.
And now, that investment of years was bearing fruit. Mr.Subbarow was coming home. Not as a refugee fleeing tragedy, but as a returning son responding to his nation's call.
The boy who should have died in 1924 was now twenty-four years old. He had grown up healthy and strong in America, educated at good schools, but he had always known the story of the mysterious Indian who had saved himself, his village and extended family.When India gained independence,he had made his own decision: he would return to the land of his father's birth and contribute to its development.
He was currently working in the R&D division of Bengal Chemicals in Calcutta, one of the brightest young researchers in the domestic pharmaceutical industry. His specialty was fermentation technology and antibiotic synthesis—skills learned partly from his famous father, partly from his own studies, and partly from the mentorship program Anirban had quietly arranged through Bengal Chemicals' management.
In the original timeline, he had never existed,. Now he was helping India achieve pharmaceutical independence.
"The ripples of a single life," Anirban whispered to the empty room, his fingers tracing the words of the telegram. "How many ripples from one life saved?"
The door opened softly. Dr. Saraswati Sinha entered, holding a briefing paper on the Indian Council of Medical Research. She had worked late into the evening, as usual, and her expression suggested she had news requiring the Prime Minister's attention.
"He agreed?" Saraswati asked, seeing the telegram on Anirban's desk and the expression on his face.
"He's coming, Madam Minister," Anirban replied, sliding the telegram across the desk so she could read it herself. "Dr. Subbarow will lead the ICMR as its Director-General. With that it won't be the ICMR the British left behind—a mere data-collection office for tropical diseases and a rubber stamp for colonial health policies. Under Subbarow, it will become the powerhouse of Indian biomedical research that we envision when Madam Amrit Kaur pressure us to restructure the ICMR."
Saraswati read the telegram carefully, her eyes widening as she absorbed the implications. She whistled softly. "Lederle Laboratories will be furious. Subbarow is their star scientist. He gave them Aureomycin. Their antibiotic patents are worth millions, and most of that value comes from his work."
"Let them be furious," Anirban said, his voice hardening. "They can be as angry as they wish while counting the profits they made from his genius without ever giving him proper credit. Dr. Subbarow is the key to our pharmaceutical independence. NIIF and the private companies are hunting for the factories and the production capacity, but Subbarow is the one who truly understands the soul of the molecule. With him at the helm of ICMR, coordinating research across our institutions, we create a closed loop."
He stood and walked to the window, looking out at the city lights of New Delhi beginning to twinkle in the gathering darkness. "We won't just manufacture antibiotics using licensed formulas and imported ingredients. We will invent the next generation of medicines. We will develop treatments specifically optimized for the diseases that afflict India—tropical diseases that Western pharmaceutical companies ignore because our people can't afford their prices. Subbarow understands this. He has seen how American companies patent molecules derived from natural sources and then charge prices that put treatments out of reach for the poor."
Anirban turned back to face Saraswati. "And there is another advantage.Others who will benefited from the medical invention of ours—children who will survived because we provided the right treatments at the right time—will scattered throughout our public sector undertakings. Some will in CSIR laboratories. Some will in the medical, engineering etc colleges we have been expanding. Some are in the pharmaceutical companies. They are the key to our future"
Saraswati looked at the Prime Minister with a mixture of awe and slight apprehension. She was beginning to understand that Anirban's "Master Plan" wasn't just written in the files of the Niti Aayog or the strategic documents locked in secure vaults. It was written in the lives of people— individuals whose survival and success had been carefully orchestrated years in advance.
"People think I'm building a country with steel and transistors, Saraswati," Anirban said softly, his voice carrying a weight that suggested he was speaking as much to himself as to her. "They look at the symposium, the industrial acquisitions, the reverse engineering programs, and they think it's about machines and factories. But I'm building it with people. Every scientist I bring back from abroad. Every child I ensured don't die. Every engineer who stays here instead of emigrating to London or Boston. Every doctor trained in our expanded medical colleges. Every researcher given opportunities that can change the world. They are the true infrastructure."
He paused, his expression becoming even more intense. "After Subbarow takes charge of ICMR, we will establish something unprecedented if Under him ICMR become, what we envision. We will lead the world in tropical medicine within a decade. We will develop vaccines for diseases the West ignores. We will create treatment protocols optimized for Indian conditions. We will build a biomedical research capability that doesn't just copy Western institutions but pioneers new approaches based on our specific needs and our specific strengths."
Saraswati absorbed this vision, her mind already working through the practical implications. Then Saraswati say"The Western delegations arrive in ten days for the treaty negotiations. The British, Americans, and French will all be sending teams to discuss trade, technology transfers, and foreign relations."
" Is not it, Good?," Anirban said, and a cold smile appeared on his face—the expression of a chess player who has just realized his opponent hasn't noticed they're already in checkmate. "By the time they sit at my negotiating table, They, Our trojan horses will already be over the Atlantic, mediterranean,. Our Trojan horses will infiltrate their fortress,Our best minds will be dispersed across the globe, extracting technology and expertise from companies and institutions that think they're engaging in routine business transactions."
He moved back to his desk and sat down, the predatory satisfaction evident in his bearing. "Let the Western delegations bring their 'aid packages' and their 'technical assistance programs' and their condescending assumptions about what India needs. They'll find that the chairs they intended to occupy are already filled. The advisory positions they planned to offer are already taken by people far more capable than the retreaded colonial administrators they wanted to send us. The technology they planned to license at inflated prices is being reverse-engineered in our laboratories even as they prepare their sales pitches."
Saraswati couldn't suppress a slight smile of her own. "They still think of us as a newly independent country that will be grateful for whatever crumbs they choose to throw our way."
"Their mistake," Anirban said flatly. "And one we will exploit thoroughly. But that's next week's concern. Tonight, we need to focus on the immediate task." He pulled out a fresh folder from his desk drawer. "Let's discuss the organizational structure for the National Institute of Molecular Biology under ICMR's umbrella. We need it operational within eighteen months."
Saraswati opened her own briefing folder. "I and Madam Amrit Kaur have already researched comparable institutions. The Americans have the National Institutes of Health, which was formalized in its current structure in 1930 and expanded during the war. The British have the Medical Research Council, established in 1920. The Soviets have the Academy of Medical Sciences, founded in 1944. All of them follow a similar model: a central coordinating body with specialized research institutes focusing on specific areas."
"The National Institute of Molecular Biology," Anirban said, Saraswati already writing notes. "NIMB for short. Its mandate will be to understand life at the molecular level—the same level at which Subbarow made his breakthrough discoveries about ATP and cellular energy. This is the cutting edge of biological science. The Americans are just beginning to understand DNA structure. The British have Crick and Watson starting their work at Cambridge. We need to be part of this revolution from the beginning, not playing catch-up a decade later."
He looked up at Saraswati. "Molecular biology is the foundation of everything—pharmaceutical development, understanding disease mechanisms, developing new treatments, even agricultural improvements through understanding plant biochemistry. NIMB will be located in Hyderabad —close enough to the newly planned and emerging pharmaceutical clusters in South India, far enough from the political pressures of Delhi that it can focus on pure research. And Hyderabad has Osmania University, which can provide a steady stream of talented graduate students."
"Osmania University?" Saraswati asked in surprise.
"Yes, to built and to run the institute under the 18 month timeline you need a place where it can be securely built and run, and as you are Nizam of Hyderabad, you are also the Chancellor of Osmania University, and Osmania University has enough land to built the Institute so you can have enough power to execute the project, and Subbarow himself will effectively lead NIMB's research direction while serving as Director-General of ICMR,"
Saraswati replied in a slump manner. " So, my workload increased again, haa!, But you know then we'll need a dedicated deputy director to handle day-to-day operations. I'm thinking of recruiting from abroad—there are Indian scientists in Britain and America doing excellent work in biochemistry who might be persuaded to return if we offer them the opportunity to build a world-class research institute from the ground up."
" Okey, do what you find suitable" He continued writing, his pen moving rapidly across the paper. "NIMB will focus on several key areas. First, fundamental research into cellular metabolism and energy transfer—building on Subbarow's ATP work. Second, understanding disease mechanisms at the molecular level, which will inform drug development. Third, developing new biochemical techniques and analytical methods that our pharmaceutical industry can use. Fourth, training the next generation of molecular biologists through an integrated graduate program with Osmania University and IISc Bangalore."
"This will require substantial funding," Saraswati noted. "The Finance Ministry is already concerned about the budget allocations for industrial development."
"Chettyji and his team will find the money," Anirban said with complete confidence. "He understands that biomedical research is not a luxury expenditure—it's an investment in human capital and national capability. NIMB will be the flagship, but we'll eventually establish a network of specialized institutes. An Institute for Nutrition to address our public health challenges. An institute of Communicable Diseases, An Institute for Malaria Research. Each one focusing on a specific area, but all coordinated through ICMR under Mr.Subbarow's direction, with NIMB serving as the center of excellence for fundamental research."
He looked directly at Saraswati. "More importantly, Chettyji understands the strategic dimension. Molecular biology is not just about treating diseases—it's about understanding the fundamental mechanisms of life itself. That knowledge has applications far beyond medicine. Agricultural productivity through understanding plant biochemistry. Industrial fermentation processes for producing antibiotics and other compounds. Even defense applications—understanding pathogens at the molecular level is essential for both protecting against biological weapons and, if necessary, developing our own deterrent capabilities. NIMB's research network will serve public health, industrial development, and national security simultaneously."
Saraswati made notes rapidly. "I'll coordinate with Chettyji on the budget allocations. What about international collaboration? Should we be seeking partnerships with the American NIH or the British MRC?"
"Selectively," Anirban replied. "We want access to their research findings and their databases, but we don't want to become dependent on them or beholden to their priorities. Subbarow's international reputation will be valuable here—he has credibility with Western institutions that will make them willing to collaborate as equals rather than treating us as recipients of their charity."
He paused, considering the larger strategic picture. "The key is to position ICMR as conducting research that the West values. Tropical diseases affect millions in Africa, Southeast Asia, and Latin America. If we develop treatments and vaccines for these diseases, Western institutions will want to collaborate with us to access those innovations. That gives us leverage. We share our tropical disease research in exchange for access to their research in other areas. Equal partnership, mutual benefit."
"And where we can't get equal partnership?"
Saraswati asked.
"Then we do it ourselves," Anirban said simply. "It will take longer and cost more, but it's better than accepting subordinate status. Subbarow understands this. He spent years watching American companies profit from his discoveries while denying him proper credit because of his Indian origin. He won't tolerate that same dynamic being imposed on India's research institutions."
They worked through the organizational details for another hour, mapping out the structure of ICMR under Subbarow's leadership, identifying priority research areas for NIMB, allocating preliminary budgets, and establishing timelines for the creation of the flagship molecular biology institute and the subsequent specialized research centers.
Finally, as the grandfather clock struck ten, Saraswati gathered her papers. "I'll have the formal organizational charter drafted by the end of next week. We can present it to Mr
Subbarow when he arrives and get his input before finalizing it. NIMB will require recruiting top-tier scientists—we should start identifying candidates immediately."
"Excellent," Anirban said. "And Saraswati? When you draft the announcement of Mr.Subbarow's appointment, make sure it emphasizes his scientific achievements. List the discoveries. Note the significance. I want every newspaper in India to understand that we're not just hiring a competent administrator—we're bringing home one of the world's leading biochemists. We're bringing home someone who chose India over the wealth and prestige of American laboratories."
"That will send a message," Saraswati observed.
"Exactly the message I want to send," Anirban confirmed. "To every Indian scientist working abroad, wondering if they should return. To every talented student considering emigration, questioning whether India can offer them opportunities equal to what they might find in the West. The answer is yes. India can offer those opportunities. India is building institutions that will rival the best in the world. And India remembers its own."
After Saraswati departed, Anirban remained at his desk, the telegram still lying there. He picked it up again, reading one phrase over and over: "coming home to pay a debt that cannot be calculated in dollars."
Yellapragada Subbarow thought he owed a debt to India for the opportunity to return and contribute to its development. He thought perhaps he owed a personal debt to the young man who had helped save his family years ago.
But from Anirban's perspective, the debt ran in the opposite direction. Every person whose life he had managed to save through carefully timed medical interventions. Every child who survived the Bengal famine because he had used his foreknowledge to redirect food supplies. Every scientist he had convinced to remain in India or return from abroad by creating opportunities that hadn't existed in the original timeline.
These were debts Anirban could never repay and never discharge. Because he had changed their timelines without their knowledge. He had saved them from deaths they never experienced, prevented tragedies they never witnessed, given them futures that had been stolen in that other version of history.
That young man now working in Bengal Chemicals, had no idea he had died at age of less than 1 year in the original timeline. He had no memory of the illness that would have killed him, no knowledge of the intervention that had saved his life. He simply lived, worked, contributed to India's pharmaceutical development, completely unaware that his very existence was a repudiation of the original timeline's cruel certainty.
How many others were there like him? How many children saved from the famine? How many disease victims who survived because Anirban had quietly ensured the right medicines were available at the right time? How many engineers and scientists whose educations had been funded by scholarships that didn't exist in the original timeline?
Hundreds, certainly. Perhaps thousands by now. A secret army of people whose lives had been altered, whose potential had been preserved, whose contributions to India's future had been made possible by interventions they never knew occurred.
"The ripples of a single life," Anirban repeated to the empty room. "But I'm not changing single lives. I'm changing thousands. And through them, changing millions."
He carefully folded the telegram and placed it in a locked drawer of his desk where he kept the most important documents—the ones too sensitive even for his official files. This telegram would stay there, a tangible reminder of what they were building and why it mattered.
Outside, New Delhi slept. But in laboratories across the country, researchers worked late into the night. In Bengal Chemicals, that young man was likely still in the lab, pursuing the same dedication to science he had inherited from his father. In hospitals and clinics, doctors trained in India's expanding medical colleges were saving lives using techniques and medicines that shouldn't exist yet in this timeline. In villages across the nation, children were surviving diseases that would have killed them in the original history.
The infrastructure of steel and transistors was important. The factories and machine tools and precision instruments were necessary.
But the true infrastructure of a nation was its people. Their lives. Their potential. Their contributions.
And Anirban was building that infrastructure one saved life at a time, one returned scientist at a time, one prevented tragedy at a time.
In two weeks, Yellapragada Subbarow would step off the plane in Bombay. He would be greeted as a returning hero, a brilliant son of India coming home to lead its biomedical research to new heights.
What he wouldn't know—what he could never know—was that his return was just one thread in a tapestry decades in the weaving. A tapestry of saved lives and altered timelines and carefully orchestrated interventions that were transforming India from what it had been into what it could be.
The Americans and British would arrive next week for their treaty negotiations, confident in their technological superiority and their ability to shape India's development to their preferences.
They had no idea that the game was already over. That the scientists they thought India would need to import were already returning home. That the technologies they planned to license at inflated prices were being reverse-engineered in secret facilities. That the dependent relationship they assumed would continue indefinitely was being systematically dismantled by a Prime Minister who knows a future they couldn't imagine.
Anirban turned off the desk lamp and stood. It was late. He should sleep. Tomorrow would bring new challenges, new decisions, new lives to save and timelines to alter.
But tonight, he allowed himself a moment of satisfaction.
Dr. Yellapragada Subbarow was coming home.
And with him came the future of Indian biomedical research.
The debt that cannot be calculated in dollars was about to be repaid in discoveries, in lives saved, in a nation's scientific independence.
And Anirban Sen, alone in his study in the dark, smiled.
As future is being rewritten.